| scholarly article | Q13442814 |
| P953 | full work available online at | http://cancerres.aacrjournals.org/cgi/content/abstract/54/21/5552 |
| P698 | PubMed publication ID | 7522961 |
| P2093 | author name string | J. Schlom | |
| S. Abrams | |||
| J. A. Kantor | |||
| J. W. Hodge | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CD antigen | Q66660268 |
| membrane glycoprotein | Q6815130 | ||
| P304 | page(s) | 5552-5555 | |
| P577 | publication date | 1994-11-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules | |
| P478 | volume | 54 |
| Q35781892 | 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines |
| Q35773889 | Antigen-presenting cell engineering. The molecular toolbox |
| Q36368136 | B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism |
| Q42119498 | CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis. |
| Q44672300 | CD86 gene variants and susceptibility to pancreatic cancer |
| Q36368968 | Cancer vaccines: current directions and perspectives in prostate cancer |
| Q36473821 | Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen |
| Q36470722 | Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. |
| Q33486534 | Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression |
| Q40764653 | Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3) |
| Q33956820 | Gene therapy for cancer: from the laboratory to the patient |
| Q41030846 | Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity |
| Q35950374 | IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. |
| Q41349071 | Immunotherapy II: Antigens, receptors and costimulation |
| Q36908784 | Initiation of primary anti-vaccinia virus immunity in vivo |
| Q36600110 | Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression |
| Q37408575 | Memory T cells need CD28 costimulation to remember |
| Q41006477 | Non-replicating expression vectors: applications in vaccine development and gene therapy |
| Q35200626 | Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy |
| Q40241848 | Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer |
| Q36412657 | Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer |
| Q45877926 | Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses |
| Q39753154 | Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming. |
| Q37180570 | Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model |
| Q40357852 | Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism |
| Q92778969 | T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity |
| Q33840446 | Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma |
| Q36470749 | The next wave of recombinant and synthetic anticancer vaccines |
Search more.